Drug intelligence / Profile preview

OC-1

Development stage: Phase 2
Lead developer: OneChain Immunotherapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous Infusion

Overview

OC-1 is an autologous CAR-T cell therapy developed by OneChain Immunotherapeutics. It involves genetically modifying a patient's own T-cells with a lentivirus to express a chimeric antigen receptor (CAR) that specifically targets the CD1a protein. Upon intravenous infusion, these engineered T-cells are designed to recognize and eliminate cancer cells expressing CD1a, primarily in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL).

Other names: CD1a-CAR TCD-1a-CAR TCD 1a-CAR ThCD1a-CAR T TherapyhCD-1a-CAR T TherapyhCD 1a-CAR T Therapy

Targets

CCR9 (C-C chemokine receptor type 9)CD1A (T-cell surface glycoprotein CD1a)

Beyond the preview

Go deeper on OC-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OC-1.

Explore the full profile